{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T21:38:48Z","timestamp":1785101928663,"version":"3.55.0"},"reference-count":28,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,1,2]]},"DOI":"10.18632\/oncotarget.22968","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T15:02:46Z","timestamp":1512572566000},"page":"293-305","source":"Crossref","is-referenced-by-count":15,"title":["Extracellular signal regulated kinase 5 and inflammasome in progression of mesothelioma"],"prefix":"10.18632","volume":"9","author":[{"given":"Joyce K.","family":"Thompson","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan L.","family":"Leggett","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip B.","family":"Munson","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian B.","family":"MacPherson","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie L.","family":"Beuschel","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey I.","family":"Pass","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Langone Medical Center, New York University, New York, NY 10012, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,12,6]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcb.24642","article-title":"Malignant mesothelioma: development to therapy","volume":"115","author":"Shukla","year":"2014","journal-title":"J Cell Biochem"},{"key":"2","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/1476-4598-9-314","article-title":"Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin","volume":"9","author":"Mossman","year":"2010","journal-title":"Mol Cancer"},{"key":"3","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/ijc.25763","article-title":"ERK2 is essential for the growth of human epithelioid malignant mesotheliomas","volume":"129","author":"Mossman","year":"2011","journal-title":"Int J Cancer"},{"key":"4","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1158\/1078-0432.CCR-12-3202","article-title":"Extracellular signal-regulated kinase 5: a potential therapeutic target for malignant mesotheliomas","volume":"19","author":"Mossman","year":"2013","journal-title":"Clin Cancer Res"},{"key":"5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1165\/rcmb.2013-0373TR","article-title":"Extracellular signal-regulated kinase 5 and cyclic AMP response element binding protein are novel pathways inhibited by vandetanib (ZD6474) and doxorubicin in mesotheliomas","volume":"51","author":"Mossman","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"key":"6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.canlet.2017.01.034","article-title":"Oncogenic signaling of MEK5-ERK5","volume":"392","author":"Burow","year":"2017","journal-title":"Cancer Lett"},{"key":"7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1165\/rcmb.2007-0206OC","article-title":"HGF mediates cell proliferation of human mesothelioma cells through a PI3K\/MEK5\/Fra-1 pathway","volume":"38","author":"Mossman","year":"2008","journal-title":"Am J Respir Cell Mol Biol"},{"key":"8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ccr.2010.08.008","article-title":"Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein","volume":"18","author":"Lee","year":"2010","journal-title":"Cancer Cell"},{"key":"9","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ajpath.2012.12.028","article-title":"New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas","volume":"182","author":"Hassan","year":"2013","journal-title":"Am J Pathol"},{"key":"10","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1126\/science.1156995","article-title":"Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica","volume":"320","author":"Tschopp","year":"2008","journal-title":"Science"},{"key":"11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1743-8977-10-39","article-title":"Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells","volume":"10","author":"Mossman","year":"2013","journal-title":"Part Fibre Toxicol"},{"key":"12","doi-asserted-by":"crossref","first-page":"e0145404","DOI":"10.1371\/journal.pone.0145404","article-title":"Inflammasome Modulation by Chemotherapeutics in Malignant Mesothelioma","volume":"10","author":"Shukla","year":"2015","journal-title":"PLoS One"},{"key":"13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ajpath.2016.11.008","article-title":"Asbestos-Induced Mesothelial to Fibroblastic Transition Is Modulated by the Inflammasome","volume":"187","author":"Shukla","year":"2017","journal-title":"Am J Pathol"},{"key":"14","doi-asserted-by":"crossref","first-page":"ra86","DOI":"10.1126\/scisignal.aaa3206","article-title":"Extracellular signal-regulated kinase 5 promotes acute cellular and systemic inflammation","volume":"8","author":"Hellman","year":"2015","journal-title":"Sci Signal"},{"key":"15","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/0008-5472.CAN-13-3043","article-title":"ERK5 is a critical mediator of inflammation-driven cancer","volume":"75","author":"Tournier","year":"2015","journal-title":"Cancer Res"},{"key":"16","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.2353\/ajpath.2009.090400","article-title":"Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis","volume":"175","author":"Mossman","year":"2009","journal-title":"Am J Pathol"},{"key":"17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ijc.25666","article-title":"Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy","volume":"129","author":"Weiss","year":"2011","journal-title":"Int J Cancer"},{"key":"18","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ijc.2910570423","article-title":"Doxorubicin retention and chemoresistance in human mesothelioma cell lines","volume":"57","author":"Krishan","year":"1994","journal-title":"Int J Cancer"},{"key":"19","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/BF00685817","article-title":"Chemosensitivity and cytokine sensitivity of malignant mesothelioma","volume":"28","author":"Robinson","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1183\/09031936.00037310","article-title":"Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study","volume":"37","author":"Sculier","year":"2011","journal-title":"Eur Respir J"},{"key":"21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.lungcan.2009.08.007","article-title":"Results of systemic pemetrexed-based combination chemotherapy versus cytoreductive surgery and hyperthermic intraperitoneal cisplatin and doxorubicin on survival in malignant peritoneal mesothelioma","volume":"66","author":"Chua","year":"2009","journal-title":"Lung Cancer"},{"key":"22","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.3892\/mmr.2017.6457","article-title":"ERK5 regulates tobacco smokeinduced urocystic epithelialmesenchymal transition in BALB\/c mice","volume":"15","author":"Zhong","year":"2017","journal-title":"Mol Med Rep"},{"key":"23","doi-asserted-by":"crossref","first-page":"11865","DOI":"10.1073\/pnas.1609019113","article-title":"ERK5 kinase activity is dispensable for cellular immune response and proliferation","volume":"113","author":"Rosenblum","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"24","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0003-4975(95)00045-M","article-title":"Characteristics of nine newly derived mesothelioma cell lines","volume":"59","author":"Matthews","year":"1995","journal-title":"Ann Thorac Surg"},{"key":"25","first-page":"3199","article-title":"Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model","volume":"47","author":"Bogden","year":"1987","journal-title":"Cancer Res"},{"key":"26","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1128\/MCB.20.4.1436-1447.2000","article-title":"Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics","volume":"20","author":"Rheinwald","year":"2000","journal-title":"Mol Cell Biol"},{"key":"27","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1158\/1940-6207.CAPR-13-0259","article-title":"Curcumin: a double hit on malignant mesothelioma","volume":"7","author":"Shukla","year":"2014","journal-title":"Cancer Prev Res (Phila)"},{"key":"28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/019262339702500605","article-title":"Growth factor responses and protooncogene expression of murine mesothelial cell lines derived from asbestos-induced mesotheliomas","volume":"25","author":"Kane","year":"1997","journal-title":"Toxicol Pathol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.22968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T10:11:15Z","timestamp":1589019075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.22968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,6]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1,2]]}},"alternative-id":["22968","29416614"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.22968","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,6]]}}}